Back to top
more

Acorda Therapeutics, Inc. (ACOR)

(Delayed Data from NSDQ)

$11.74 USD

11.74
1,452,260

+1.16 (10.96%)

Updated May 3, 2019 04:00 PM ET

After-Market: $11.74 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Acorda Therapeutics (ACOR) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Acorda (ACOR) delivered earnings and revenue surprises of 23.33% and 80.64%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Acorda Therapeutics (ACOR) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

by Zacks Equity Research

Acorda (ACOR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Are Options Traders Betting on a Big Move in Acorda Therapeutics (ACOR) Stock?

by Zacks Equity Research

Investors need to pay close attention to Acorda Therapeutics (ACOR) stock based on the movements in the options market lately.

Acorda Therapeutics (ACOR) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Acorda (ACOR) delivered earnings and revenue surprises of 23.91% and 27.56%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Teladoc (TDOC) Soars 193% in a Year: What's Behind the Rally?

by Zacks Equity Research

Teladoc (TDOC) continues to benefit from constant top-line growth and strategic initiatives, which have been aiding its share price.

Is the Options Market Predicting a Spike in Acorda Therapeutics (ACOR) Stock?

by Zacks Equity Research

Investors need to pay close attention to Acorda Therapeutics (ACOR) stock based on the movements in the options market lately.

Acorda (ACOR) Down 11.8% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Acorda (ACOR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Acadia Healthcare Ties Up for Improved Behavioral Services

by Zacks Equity Research

Acadia Healthcare (ACHC) partners with Covenant Health for offering improved mental health services in East Tennessee.

Acorda (ACOR) Q1 Earnings Lag Estimates, Revenues Fall Y/Y

by Zacks Equity Research

Acorda's (ACOR) earnings and revenues fall shy of estimates in the first quarter of 2020. The company withdraws revenue view for its Parkinson's disease drug Inbrija due to the ongoing COVID-19 pandemic.

Acorda Therapeutics (ACOR) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Acorda (ACOR) delivered earnings and revenue surprises of -45.71% and -28.58%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Acorda (ACOR) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

During Acorda's (ACOR) upcoming Q1 earnings call, investor focus will be on the sales uptake of its newly-launched Parkinson's disease drug, Inbrija.

Acorda Therapeutics (ACOR) Flat As Market Gains: What You Should Know

by Zacks Equity Research

Acorda Therapeutics (ACOR) closed the most recent trading day at $1.06, making no change from the previous trading session.

Immunomedics' Sacituzumab Govitecan Gets Fast Track Tag for UC

by Zacks Equity Research

The FDA bestows a fast track status on Immunomedics' (IMMU) sacituzumab govitecan for treating adult patients with locally advanced or metastatic urothelial cancer (mUC).

Acorda Therapeutics (ACOR) Stock Moves -0.11%: What You Should Know

by Zacks Equity Research

Acorda Therapeutics (ACOR) closed the most recent trading day at $0.93, moving -0.11% from the previous trading session.

Axsome's AXS-07 Meets Co-Primary Goals in Migraine Study

by Zacks Equity Research

Axsome's (AXSM) AXS-07 achieves both regulatory co-primary endpoints in the phase III INTERCEPT study for the early treatment of migraine.

Mallinckrodt Starts Rolling BLA Filing for StrataGraft Tissue

by Zacks Equity Research

Mallinckrodt (MNK) begins rolling submission of BLA for StrataGraft regenerative skin tissue therapy to the FDA for addressing adult patients with deep partial-thickness thermal burns. Stock rises.

Seattle Genetics Issue Update on Padcev Label Expansion Study

by Zacks Equity Research

Seattle Genetics (SGEN) may receive an expedited approval pathway for Padcev combo to treat patients with locally advanced/metastatic urothelial cancer in the first-line setting in the United States.

Immunomedics (IMMU) in Focus: Stock Moves 5% Higher

by Zacks Equity Research

Immunomedics (IMMU) saw a big move last session, as its shares jumped nearly 5% on the day, amid huge volumes.

Mesoblast's (MESO) BLA for Ryoncil Gets FDA Priority Review

by Zacks Equity Research

The FDA accepts Mesoblast's (MESO) BLA for Ryoncil (remestemcel-L) under a priority review to treat children with steroid-refractory acute graft versus host disease. A decision is pending on Sep 30.

Nabriva (NBRV) Looks Good: Stock Adds 5.7% in Session

by Zacks Equity Research

Nabriva (NBRV) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Axsome's (AXSM) AXS-05 Fails to Meet Main Goal in TRD Study

by Zacks Equity Research

Axsome's (AXSM) AXS-05 meets key secondary endpoints in late-stage study for addressing patients with treatment resistant depression. However, the primary endpoint did not reach statistical significance.

Nitish Marwah headshot

New Strong Buy Stocks for March 30th

by Nitish Marwah

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today.

What Makes Acorda (ACOR) a New Buy Stock

by Zacks Equity Research

Acorda (ACOR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Why Is Acorda (ACOR) Down 54.7% Since Last Earnings Report?

by Zacks Equity Research

Acorda (ACOR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Acorda (ACOR) Q4 Earnings Top Estimates, Revenues Fall Y/Y

by Zacks Equity Research

Acorda (ACOR) beat earnings and revenue estimates in the fourth quarter of 2019.